Trials / Completed
CompletedNCT04226274
A Study of the Safety of REN001 in Patients With McArdle Disease
A Phase 1b, Open-label Study to Evaluate the Safety and Tolerability of 12 Weeks Treatment With Oral REN001 in Patients With McArdle Disease (Glycogen Storage Disorder 5)
- Status
- Completed
- Phase
- Phase 1
- Study type
- Interventional
- Enrollment
- 19 (actual)
- Sponsor
- Reneo Pharma Ltd · Industry
- Sex
- All
- Age
- 18 Years
- Healthy volunteers
- Not accepted
Summary
The purpose of this study is to assess REN001 safety in subjects with McArdle Disease
Conditions
Interventions
| Type | Name | Description |
|---|---|---|
| DRUG | REN001 | Once daily for 12 weeks |
Timeline
- Start date
- 2019-12-10
- Primary completion
- 2021-10-11
- Completion
- 2021-10-11
- First posted
- 2020-01-13
- Last updated
- 2022-01-12
Locations
2 sites across 2 countries: Spain, United Kingdom
Source: ClinicalTrials.gov record NCT04226274. Inclusion in this directory is not an endorsement.